SCHEMBL2808690

SCHEMBL2808690

COC(=O)C(=Cc1cccc(O)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.40
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 2/20 0.39
NQO2 P16083 1/20 0.39
HPGD P15428 2/20 0.38
LMNA P02545 1/20 0.38
GFER P55789 1/20 0.38
P4HB P07237 1/20 0.37
MMP1 P03956 2/20 0.36
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808687 1.00 MIF (0.40) MIFKDM4EALDH1A1MAPTRAB9A
SCHEMBL13125661 1.00 MIF (0.40) MIFKDM4EALDH1A1MAPTRAB9A
SCHEMBL8364952 0.87 NPSR1 (0.38) MIFKDM4EALDH1A1MAPTRAB9A
SCHEMBL5140504 0.87 NPSR1 (0.38) MIFKDM4EALDH1A1MAPTRAB9A
SCHEMBL5140506 0.87 NPSR1 (0.38) MIFKDM4EALDH1A1MAPTRAB9A
SCHEMBL8364996 0.87 SMN1; SMN2 (0.40) KDM4EALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL4883097 0.87 SMN1; SMN2 (0.40) KDM4EALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL13906650 0.86 LMNA (0.44) KDM4EALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL9135881 0.82 ALDH1A1 (0.53) KDM4EALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL9135884 0.82 ALDH1A1 (0.53) KDM4EALDH1A1MAPTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
WO-2010108059-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR INCYTE CORPORATION (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS HRH4, HRH2, HRH1 MIF 1729/4885KDM4E 1238/4885ALDH1A1 1903/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 MIF 1394/4885KDM4E 972/4885ALDH1A1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.